# reload+after+2024-01-23 11:47:22.617537
address1§171 Oyster Point Boulevard
address2§Suite 400
city§South San Francisco
state§CA
zip§94080
country§United States
phone§650 489 9000
website§https://www.surrozen.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.
fullTimeEmployees§74
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Craig C. Parker M.B.A.', 'age': 61, 'title': 'CEO, President & Director', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 753300, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Charles  Williams', 'age': 43, 'title': 'CFO & Corporate Secretary', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 563489, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. K. Christopher  Garcia Ph.D.', 'title': 'Co-Founder & Member of Scientific Advisor', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Roeland  Nusse Ph.D.', 'age': 73, 'title': 'Co-Founder & Member of Scientific Advisor', 'yearBorn': 1950, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Calvin  Kuo M.D., Ph.D.', 'title': 'Co-Founder & Member of Scientific Advisor', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Li  Yang Ph.D.', 'title': 'Executive Vice President of Research', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Esther  Jhun', 'title': 'Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.398
priceToSalesTrailing12Months§1.7170976
currency§USD
dateShortInterest§1702598400
forwardEps§-10.12
pegRatio§-0.02
exchange§NCM
quoteType§EQUITY
shortName§Surrozen, Inc.
longName§Surrozen, Inc.
firstTradeDateEpochUtc§1610375400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f300e438-31d2-353a-a98a-8e2cc4bb3308
gmtOffSetMilliseconds§-18000000
targetHighPrice§60.0
targetLowPrice§7.5
targetMeanPrice§33.75
targetMedianPrice§33.75
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§6.806
grossMargins§-1.44576
ebitdaMargins§-2.686
trailingPegRatio§None
